Poly Medicure Limited has issued a clarification to BSE Limited regarding the significant increase in trading volume of its securities across exchanges in recent times. The response came following an inquiry from BSE dated January 7, 2026, seeking explanation for the unusual volume movement.

Company's Response to Volume Inquiry

The healthcare company categorically stated that there is no information or announcement, including any impending announcement, that could have a bearing on the price or volume behavior of the company's scrip as traded across exchanges. The company emphasized that such information, if it existed, would be required to be disclosed to stock exchanges under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Market-Driven Movement

Poly Medicure Limited attributed the volume movement in its securities to purely market conditions, describing it as "absolutely market driven." The company's management made it clear that the trading activity was not influenced by any internal developments or undisclosed information that would typically trigger such movements.

Regulatory Compliance Confirmation

The company reaffirmed its commitment to regulatory compliance, stating that it has been regularly disseminating unpublished price sensitive information as and when required. This disclosure practice follows the guidelines of:

• SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
• SEBI (Prohibition of Insider Trading) Regulations, 2015

The clarification was signed by Avinash Chandra, Company Secretary (Membership No: A32270), and submitted to BSE Limited at P J Towers, Dalal Street, Mumbai. The company expressed confidence that the response adequately addressed BSE's query regarding the volume movement.

Poly Medicure Limited, a leading medical device manufacturer, has reported a 5.7% year-on-year growth in consolidated revenue for Q2, reaching Rs 444.00 crores. The company has also successfully completed two strategic acquisitions worth Rs 280.00 crores, positioning itself for future growth in the global medical device market.

Financial Performance

Poly Medicure achieved a consolidated revenue of Rs 444.00 crores in Q2, marking a 5.7% year-on-year growth and a 10.1% quarter-on-quarter increase. The company's gross profit for the quarter stood at Rs 308.00 crores, reflecting a margin of 69.4%, an improvement of 99 basis points compared to the same quarter last year.

The operating EBITDA for Q2 was Rs 119.00 crores, with a margin of 26.8%, slightly lower than the 26.76% reported in the previous year. This figure excludes one-time acquisition costs of Rs 3.20 crores related to the PendraCare Group acquisition.

Strategic Acquisitions

Poly Medicure has completed two significant acquisitions:

1. Italy-based Citieffe Group: A leading player in the orthopedic trauma space and extremities business, expanding Poly Medicure's total addressable market by approximately $70.00 billion globally.

2. Netherlands-based PendraCare Group: A specialist in interventional cardiology solution catheters, strengthening Poly Medicure's Cardiology segment and providing manufacturing and distribution footprint in Europe.

These acquisitions are expected to add around Rs 280.00 crores of annual revenue to Poly Medicure's existing business.

Market Challenges and Growth Strategies

While facing headwinds in European markets and US tariff challenges, Poly Medicure has maintained a positive outlook. The company has guided for H2 revenue of Rs 1,080.00-1,090.00 crores, representing a 25% increase over H1. The management has also maintained its operating EBITDA margin guidance of 25-27%.

Domestic Market Performance

The domestic revenue for Q2 and H1 grew by 17-18% year-on-year, reflecting effective strategy execution and rising demand for Poly Medicure's offerings locally. The private business segment showed strong growth of 22.3% year-on-year in Q2, while the government business experienced a 14% decline.

International Business

The international business segment is showing signs of recovery, with Q2 revenue of around Rs 300.00 crores, representing a 9.1% quarter-on-quarter growth. The company is witnessing green shoots in recovering international markets and remains cautiously optimistic for H2 of the current financial year.

Future Outlook

Poly Medicure is focusing on several growth initiatives:

1. Expanding its product portfolio with 20 new products expected to receive CE certification.
2. Investing in new manufacturing facilities in India, including expansions in Faridabad, Haridwar, and a new facility near Jewar airport.
3. Continuing to invest in the US market despite current tariff challenges, with new product launches planned.
4. Strengthening its presence in Cardiology and Critical Care segments, with ongoing clinical trials for products like the RisoR stent.

Poly Medicure's management remains confident in the company's growth trajectory, expecting to return to its original growth target of 20% in the coming years, supported by new product launches and increased manufacturing capacity.

As Poly Medicure navigates through market challenges and capitalizes on strategic acquisitions, the company appears well-positioned to strengthen its presence in both domestic and international medical device markets.